Using Early Evidence Generation to Drive Commercial Success
About this webinar
Delaying the design and execution of an evidence strategy can lead to irreversible consequences for market access, pricing and health technology assessment outcomes.
This webinar explores the strategic value of early evidence generation in biotech development, focusing on what data is needed, when it matters and how emerging companies can build a fit-for-purpose plan to support both partnerships and reimbursement goals.
Drawing from real-world examples and market trends, this webinar highlights the risks of poor planning and the benefits of early, integrated evidence strategies.
It will outline what constitutes “fit-for-purpose” data, when it is needed and how to align evidence generation with business development and reimbursement goals. Attendees will learn how timely evidence planning can reduce uncertainty, support pricing and access and enhance partnership potential.
Register for this webinar to discover why delaying evidence generation by even two years can cost you access, pricing and partnerships.
Who should attend
- Chief Executive Officer (CEO)
- Chief Commercial Officer (CCO)
- Chief Medical Officer (CMO)
- Chief Development Officer (CDO)
- Head/Director/VP of Evidence Generation
- Head/Director/VP of Medical Affairs
- Head/Director/VP of Market Access
- Head/Director/VP of Health Economics & Outcomes Research (HEOR)
- Head/Director/VP of Clinical Development
- Head/Director/VP of Regulatory Affairs
- Business Development & Licensing (BD&L) Leaders
- Commercial Strategy Leaders
- Market Access & Pricing Managers
- HEOR & RWE (Real-World Evidence) Managers
- Clinical Operations & Development Managers
- Medical Affairs Managers
- Early Access Program Leaders
- Portfolio & Pipeline Strategy Leaders
What you will learn
- What constitutes “fit-for-purpose” evidence for different stages of development
- How evidence generation ties directly into BD, pricing and HTA success
- Why delayed planning can erode product value and how to avoid it
Featured Speakers
Noolie Gregory
Noolie has over 20 years of experience in the pharmaceutical and CRO sectors, with expertise in clinical development, medical affairs, real-world and late-phase studies and early access programs. She has a strong track record of driving results across multiple therapeutic areas, particularly oncology. In recent years, she has focused on patient- and site-facing technologies to enhance study delivery and patient experience. Now Head of Evidence Generation at Sciensus, Noolie works across all service lines to support clients in maximising patient interactions and generating real-world insights through RWLP study designs and early access programs.
Andrew Cummins
Andrew Cummins is the Vice President of Business Development at Sciensus. He is a seasoned business development leader with 30 years of experience in rare diseases, specialising in driving access from clinical trials to market through strategic partnerships and innovative solutions.
Partner for this event
Sciensus
Sciensus is a leading European life sciences organisation with over 30 years of experience. We’re redefining patient-centric care, connecting patients with life-changing medicines while empowering pharmaceutical companies and healthcare professionals with the insights needed to improve people’s lives.